PepGen (PEPG) Stock Price, News & Analysis

Company Overview

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $2.30 to $2.45
• 50-Day Range: $2.30 to $6.35
• 52-Week Range: $2.30 to $19.30
• Volume: 131,834 shs
• Average Volume: 244,938 shs
• Market Capitalization: $74.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.67
• Consensus Rating: Hold

PepGen Stock Analysis - MarketRank™

PepGen scored higher than 61% of companies evaluated by MarketBeat, and ranked 460th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

PepGen has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

PepGen has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PepGen are expected to grow in the coming year, from ($2.73) to ($2.56) per share.

Price to Book Value per Share Ratio

PepGen has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.64% of the float of PepGen has been sold short.

Short Interest Ratio / Days to Cover

PepGen has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in PepGen has recently decreased by 14.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PepGen does not currently pay a dividend.

Dividend Growth

PepGen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.64% of the float of PepGen has been sold short.

Short Interest Ratio / Days to Cover

PepGen has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in PepGen has recently decreased by 14.09%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.95

News Sentiment

PepGen has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for PepGen this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for PEPG on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

MarketBeat Follows

3 people have added PepGen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PepGen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of PepGen is held by insiders.

Percentage Held by Institutions

58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PEPG Stock Analysis - Frequently Asked Questions

How have PEPG shares performed this year?

PepGen's stock was trading at $3.79 at the beginning of 2025. Since then, PEPG shares have decreased by 39.3% and is now trading at $2.30.
View the best growth stocks for 2025 here.

How were PepGen's earnings last quarter?

PepGen Inc. (NASDAQ:PEPG) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.15.

When did PepGen IPO?

PepGen (PEPG) raised $126 million in an IPO on Friday, May 6th 2022. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share.

How do I buy shares of PepGen?

Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PepGen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PepGen investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), Home Depot (HD) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 1/20/2025
• Next Earnings (Estimated): 3/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PEPG
• CUSIP: N/A
• CIK: 1835597
• Web: www.pepgen.com
• Phone: 781-797-0979
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.67
• High Stock Price Target: $26.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +494.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-78,630,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -60.17%
• Return on Assets: -48.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.47
• Quick Ratio: 8.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.55 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 32,600,000
• Free Float: 31,097,000
• Market Cap: $74.98 million
• Optionable: Not Optionable
• Beta: 1.66